x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011529
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Recombinant fragment |
| Applications | WB, Sandwich ELISA |
| Product Description | Biotin Rabbit polyclonal antibody to Adiponectin. |
| Format | Lyophilized: Reconstitute in sterile PBS with 0.1% BSA to 0.1-1.0 mg/mL. |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ADIPOQ |
| UniProt No. | Q15848 |
| Gene ID | 9370 |
| Gene Description | Important adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic and anti-inflammatory activities. Stimulates AMPK phosphorylation and activation in the liver and the skeletal muscle, enhancing glucose utilization and fatty-acid combustion. Antagonizes TNF-alpha by negatively regulating its expression in various tissues such as liver and macrophages, and also by counteracting its effects. Inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway. May play a role in cell growth, angiogenesis and tissue remodeling by binding and sequestering various growth factors with distinct binding affinities, depending on the type of complex, LMW, MMW or HMW. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at +4 °C short term (1-2 weeks). Upon delivery aliquot. Store at -20 °C long term. Avoid freeze / thaw cycle. Store In the Dark. |
| Storage Buffer | Constituents: PBS, 0.1% BSA |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
